洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2500108726】The effects of theory-guided multimodal educational (TIME) programme on the faecal occult blood test uptake rates among adults at average-risk of colorectal cancer: A randomized controlled trial

基本信息
登记号

ChiCTR2500108726

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2025-09-04

临床申请受理号

/

靶点

/

适应症

Colorectal cancer

试验通俗题目

The effects of theory-guided multimodal educational (TIME) programme on the faecal occult blood test uptake rates among adults at average-risk of colorectal cancer: A randomized controlled trial

试验专业题目

The effects of theory-guided multimodal educational (TIME) programme on the faecal occult blood test uptake rates among adults at average-risk of colorectal cancer: A randomized controlled trial

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

i) To develop and implement the TIME programme among adults at average-risk of colorectal cancer (CRC). ii) To examine the effects of TIME programme on CRC uptake rates, perceived susceptibility to CRC, perceived severity of CRC, perceived barriers to CRC screening, perceived benefits of CRC screening, and self-efficacy. iii) To evaluate the participants’ satisfaction with the TIME programme.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

Block randomization will be used to assign the participants to the intervention group or wait-list control group in a 1:1 ratio with a block size of 8. An independent statistician will use a computer to generate a random assignment sequence of group identifiers. The sequence of group identifiers will be printed on identical cards and inserted into sequentially numbered, sealed opaque envelopes.

盲法

Due to the nature of the educational intervention and the use of a wait-list control group in this study, it is not possible for the study participants to be blinded to their group allocation.

试验项目经费来源

N/A

试验范围

/

目标入组人数

104

实际入组人数

/

第一例入组时间

2025-08-15

试验终止时间

2026-08-31

是否属于一致性

/

入选标准

1. aged between 50 and 75; 2. Hong Kong residents; 3. no symptoms of CRC; 4. no history of CRC, polyps or inflammatory bowel disease; 5. no family history of CRC; 6. able to access WhatsApp Messenger or WeChat; 7. able to read Chinese and communicate in Cantonese; 8. willing to be followed up by telephone.;

排除标准

Individuals who have undergone a faecal occult blood test (FOBT) in the past 2 years, a sigmoidoscopy in the past 5 years, or a colonoscopy in the past 10 years, as well as those who do not have a smartphone, are mentally incapable, have hearing or visual impairments, or are unable to provide informed consent will be excluded.;

研究者信息
研究负责人姓名
请登录查看
试验机构

The Chinese University of Hong Kong

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

The Chinese University of Hong Kong的其他临床试验

The Chinese University of Hong Kong的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

383,318
全球在研药物数
964
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,630亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看